Literature DB >> 7583160

The acute-phase response.

B H Pannen1, J L Robotham.   

Abstract

Inflammation and tissue injury elicit profound changes in the concentrations of several plasma proteins. These proteins are predominantly synthesized in the liver and named acute-phase proteins. The regulatory mechanisms that control this response are highly complex and include the release of various mediators affecting specific subsets of acute-phase genes. Individual mediators can either synergistically enhance or inhibit the effects of other mediators. Binding of mediators to their respective receptors on hepatocytes and transduction of this signal induce changes in acute-phase protein gene expression that are primarily regulated on a transcriptional level. However, under certain conditions post-transcriptional mechanisms may also be involved in this process. Although some acute-phase proteins have been shown to minimize tissue damage, as well as to participate in hemostasis, tissue repair, and regeneration in response to injury, the actual in vivo functions of several acute-phase reactants remain speculative. Measurements of acute-phase protein plasma concentrations can be of diagnostic or prognostic value under certain clinical conditions. Further characterization of the regulatory mechanisms that govern the acute-phase response in vivo could lead to the development of new therapeutic strategies aimed at improving the organism's integrated response to injury.

Mesh:

Substances:

Year:  1995        PMID: 7583160

Source DB:  PubMed          Journal:  New Horiz        ISSN: 1063-7389


  20 in total

1.  A sentinel function for teat tissues in dairy cows: dominant innate immune response elements define early response to E. coli mastitis.

Authors:  Manuela Rinaldi; Robert W Li; Douglas D Bannerman; Kristy M Daniels; Christina Evock-Clover; Marcos V B Silva; Max J Paape; Bernadette Van Ryssen; Christian Burvenich; Anthony V Capuco
Journal:  Funct Integr Genomics       Date:  2009-08-29       Impact factor: 3.410

Review 2.  [Sepsis. Update on pathophysiology, diagnostics and therapy].

Authors:  M Bauer; F Brunkhorst; T Welte; H Gerlach; K Reinhart
Journal:  Anaesthesist       Date:  2006-08       Impact factor: 1.041

3.  Characterization of lipopolysaccharide-stimulated cytokine expression in macrophages and monocytes.

Authors:  Haiqiu Huang; Arnetta Fletcher; Yuge Niu; Thomas T Y Wang; Liangli Yu
Journal:  Inflamm Res       Date:  2012-07-28       Impact factor: 4.575

4.  Mini-laparotomy and full laparotomy, but not laparoscopy, alter hepatic macrophage populations in a rat model.

Authors:  N K Jesch; G Vieten; T Tschernig; W Schroedel; B M Ure
Journal:  Surg Endosc       Date:  2005-05-04       Impact factor: 4.584

5.  Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor.

Authors:  Carmen Martinez; Catalina Abad; Mario Delgado; Alicia Arranz; Maria G Juarranz; Nieves Rodriguez-Henche; Philippe Brabet; Javier Leceta; Rosa P Gomariz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

6.  Protective role of endogenous carbon monoxide in hepatic microcirculatory dysfunction after hemorrhagic shock in rats.

Authors:  B H Pannen; N Köhler; B Hole; M Bauer; M G Clemens; K K Geiger
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

7.  Sepsis-induced inflammation is exacerbated in an animal model of type 2 diabetes.

Authors:  Asha Jacob; Marissa L Steinberg; Juntao Yang; Weifeng Dong; Youxin Ji; Ping Wang
Journal:  Int J Clin Exp Med       Date:  2008-01-10

Review 8.  Immune surveillance by the liver.

Authors:  Craig N Jenne; Paul Kubes
Journal:  Nat Immunol       Date:  2013-09-18       Impact factor: 25.606

9.  What's new in Emergencies, Trauma and Shock? Coagulation is in the focus!

Authors:  Max Ragaller
Journal:  J Emerg Trauma Shock       Date:  2010-01

Review 10.  [Acute liver failure. Current aspects of diagnosis and therapy].

Authors:  M Bauer; M Paxian; A Kortgen
Journal:  Anaesthesist       Date:  2004-06       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.